SavedAdd your journal

Journals / Journal of Experimental and Clinical Medicine / 2026 / Volume: 39 Issue: 2

Abciximab-induced thrombocytopenia: correct management

Engin Kelkitli(ONDOKUZ MAYIS UNIVERSITY, SCHOOL OF MEDICINE)0000-0001-7342-1760
Aslı Odabaşı Giden(ONDOKUZ MAYIS UNIVERSITY, SCHOOL OF MEDICINE)0000-0001-7375-4485
Derya Deniz Kürekçi(ONDOKUZ MAYIS UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-0537-9289
Mehmet Turgut(ONDOKUZ MAYIS UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-1036-0232
Pages
—
Publication Date
2022-03-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thrombocytopenia is a possible side effect of routinely administered medical agents.
📊
Key Findings & Data:Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus.
💡
Conclusion & Impact:In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:Abciximab · glycoprotein IIb/IIIa receptor inhibitors · side effect

Abstract

Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.

🔖

Cite This Article

Kelkitli, E., Giden, A. O., Kürekçi, D. D., Turgut, M. (2022). Abciximab-induced thrombocytopenia: correct management. Journal of Experimental and Clinical Medicine, Volume: 39 Issue: 2. https://ajindex.com/articles/1423090

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Nowakowski, K., et al., Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol, 2008. 21(1): p. 100-5.
  2. George, J.N. and R.H. Aster, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program, 2009: p. 153-8.
  3. Arnold, D.M., et al., A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost, 2013. 11(1): p. 169-76.
  4. Park, S., et al., Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Korean Circ J, 2013. 43(8): p. 557-60.
  5. Aster, R.H., et al., Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006. 4(3): p. 678-9.
  6. Golden, T., et al., Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep, 2017. 2017.
  7. Curtis, B.R., et al., Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost, 2004. 2(6): p. 985-92.
  8. Aster, R.H. and D.W. Bougie, Drug-induced immune thrombocytopenia. N Engl J Med, 2007. 357(6): p. 580-7.
  9. Llevadot, J., S.A. Coulter, and R.P. Giugliano, A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis, 2000. 9(2): p. 175-80.
  10. Giupponi, L., et al., Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets, 2015. 26(5): p. 498-500.
  11. Arnold, D.M., et al., Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013. 27(3): p. 137-45.
  12. Bakchoul, T. and I. Marini, Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program, 2018. 2018(1): p. 576-583.
  13. Piątek, Ł., et al., Delayed severe abciximab-induced thrombocytopenia: A case report. Heart Lung, 2016. 45(5): p. 464-5.